Shareholders to Vote on Significant Equity Plan Expansion and NOL Protection Plan

summarizeSummary

Heron Therapeutics' definitive proxy statement details proposals for its annual meeting, including a significant increase in shares for equity incentive and employee stock plans, potentially diluting existing shareholders by over 14%, and the advisory ratification of a Tax Benefits Preservation Plan to protect NOLs.

check_boxKey Events

• Proposed Increase in Equity Incentive Plan Shares

  Shareholders will vote on amending the 2007 Equity Incentive Plan to authorize an additional 16,560,000 shares of common stock for issuance. This represents a potential dilution of approximately 8.78% based on 188,638,866 shares outstanding as of April 14, 2026. The company's overhang, including this increase, would rise from 15.8% to 21.6%.

• Proposed Increase in Employee Stock Purchase Plan Shares

  The company is seeking approval to amend its 1997 Employee Stock Purchase Plan (ESPP) to increase the number of authorized shares by an additional 10,000,000. This proposal alone represents a potential dilution of approximately 5.30% based on current outstanding shares.

• Advisory Vote on Tax Benefits Preservation Plan

  Shareholders will cast a nonbinding advisory vote on the adoption of a Tax Benefits Preservation Plan (poison pill). This plan is intended to protect the company's significant federal and state Net Operating Loss (NOL) carryforwards, valued at approximately $2.1 billion as of December 31, 2025, from potential impairment under Section 382 of the Internal Revenue Code.

• Annual Meeting Scheduled

  The 2026 Annual Meeting of Stockholders will be held virtually on June 11, 2026, where shareholders will vote on these and other routine corporate governance matters, including the election of directors and executive compensation.

auto_awesomeAnalysis

Heron Therapeutics has filed its definitive proxy statement for the upcoming annual meeting, outlining several key proposals for shareholder vote. The most impactful proposals involve a substantial increase in authorized shares for both the 2007 Equity Incentive Plan and the 1997 Employee Stock Purchase Plan (ESPP). If approved, these amendments would authorize an additional 16,560,000 shares for the incentive plan and 10,000,000 shares for the ESPP, representing a combined potential dilution of approximately 14.08% based on current outstanding shares. This significant potential dilution could weigh on the stock, though the company frames it as necessary for attracting and retaining key personnel and fostering employee ownership. Additionally, shareholders will vote on the advisory ratification of a Tax Benefits Preservation Plan (poison pill), designed to protect the company's substantial Net Operating Loss (NOL) carryforwards from impairment due to ownership changes. While a defensive measure, protecting NOLs is a strategic move given the company's financial position.